Quick Answer
Eton Pharmaceuticals, Inc. reported R&D Expense of $7.76 million for fiscal year 2025.
Eton Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $7.76M | +138.6% |
| 2024 | $3.25M | -2.0% |
| 2023 | $3.32M | -16.9% |
| 2022 | $4.00M | -35.9% |
| 2021 | $6.24M | -55.8% |
| 2020 | $14.10M | +22.1% |
| 2019 | $11.55M | +105.3% |
| 2018 | $5.63M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.11M | +120.2% | -70.0% |
| June 30, 2025 | $3.71M | +25.0% | +219.7% |
| March 31, 2025 | $1.16M | +78.3% | +129.9% |
| September 30, 2024 | $505.0K | -17.9% | -83.0% |
| June 30, 2024 | $2.97M | +164.0% | +356.2% |
| March 31, 2024 | $651.0K | +21.7% | +5.9% |
| September 30, 2023 | $615.0K | -17.3% | -45.3% |
| June 30, 2023 | $1.12M | +63.0% | +110.3% |
- Eton Pharmaceuticals, Inc. showed an increase of +138.6% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, Eton Pharmaceuticals, Inc.’s r&d expense has grown by 38.0% (from $5.63 million to $7.76 million).
- The most recent figure is from Eton Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: